Men's Health News

RSS

MU nanomedicine experts form new partnership with Shasun Pharmaceuticals

University of Missouri leaders celebrated a nanomedicine milestone today as they announced the creation of a new drug development company. The new company forms a partnership between university researchers and an international pharmaceutical firm to advance testing of a potential cancer treatment created at MU.

3 Dec 2010

Olympus PlasmaButton- vaporization technology now usable with Gyrus ACMI SuperPulse- Generator platform

Olympus, a precision technology leader in designing and delivering innovative solutions in Medical and Surgical Products among other core businesses, announced today that its revolutionary PlasmaButton- vaporization technology can now be used with the Gyrus ACMI SuperPulse- Generator platform. Together, the PlasmaButton electrode and SuperPulse Generator provide physicians and patients with a new, virtually bloodless treatment option for benign prostate hyperplasia (BPH) or enlarged prostate.

From Evident Corporation - Life Sciences 3 Dec 2010

FDA panel rejects expansion of drug label

The New York Times: A Food and Drug Administration advisory committee on Tuesday rejected a bid to change the labels of two drugs to say they can reduce the risk of prostate cancer. "If the drugs were approved for that purpose, they would be only the second class of cancer-prevention drugs on the market."

2 Dec 2010

FDA advisory committee votes against Avodart sNDA for prostate cancer risk reduction

GlaxoSmithKline today announced the results of a U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) meeting to discuss the supplemental New Drug Application (sNDA) for Avodart® (dutasteride) for reducing the risk of prostate cancer in men at risk for the disease, defined as those who have had a prior negative biopsy due to clinical concern and have an elevated serum prostate-specific antigen (PSA).

2 Dec 2010

American-style diet plays a vital role in prostate cancer, researchers say

Elevated fat and cholesterol levels found in a typical American-style diet plays an important role in the growth and spread of prostate cancer, say researchers at Thomas Jefferson University's Kimmel Cancer Center.

2 Dec 2010

Finger length may predict prostate cancer

In a new study published in the British Journal of Cancer, researchers have revealed a connection between finger length and prostate cancer. It says that men whose ring fingers are longer than their index fingers are more likely to develop prostate cancer.

1 Dec 2010

Active surveillance improves quality of life in low-risk prostate cancer patients

In a study that compared initial treatment strategies for low-risk prostate cancer among men 65 years old, active surveillance showed higher measures on quality of life compared to an initial treatment such as radical prostatectomy, although the optimal strategy was highly dependent on individual patient preferences for surveillance or treatment, according to a study in the December 1 issue of JAMA.

1 Dec 2010

Men with long index fingers at lower risk of prostate cancer

Men who have long index fingers are at lower risk of prostate cancer, a new study published today in the British Journal of Cancer has found.

1 Dec 2010

Researchers conduct real-time metabolic imaging in human patient with prostate tumor

A UCSF research collaboration with GE Healthcare has produced the first results in humans of a new technology that promises to rapidly assess the presence and aggressiveness of prostate tumors in real time, by imaging the tumor's metabolism.

30 Nov 2010

Medivation, Astellas enroll 1,199 patients in MDV3100 Phase 3 AFFIRM study in advanced prostate cancer

Medivation, Inc. and Astellas Pharma Inc. today announced that patient enrollment was completed on November 15, 2010 in the Phase 3 AFFIRM study of the investigational drug MDV3100, a novel, triple-acting oral androgen receptor antagonist, in patients with advanced prostate cancer who have previously been treated with chemotherapy. The companies also announced that clinical development of MDV3100 in Japan has commenced, with the initiation of patient dosing in a Phase 1-2 clinical study.

30 Nov 2010

FDA approves Axiron topical solution CIII for testosterone replacement therapy in men

Acrux , a drug delivery company that develops and commercializes patented pharmaceutical products for global markets, and Eli Lilly Company today announced that the United States Food and Drug Administration (FDA) has approved the Axiron® topical solution CIII for testosterone replacement therapy in men. Axiron is the first testosterone topical solution approved for application via an underarm applicator.

29 Nov 2010

Study finds association between DGKK gene and hypospadias

Hypospadias is a common congenital malformation of the male external genitalia, affecting 1 in 375 boys. In hypospadias patients, the urethral opening is not located at the tip of the penis, but somewhere halfway, at the base of the penis, or even in the scrotum.

29 Nov 2010

ESF report: Reduced male fertility may contribute to low birth rates

Reduced male fertility may be making it even harder for couples to conceive and be contributing to low birth rates in many countries, reveals a new European Science Foundation (ESF) report launching today at the IPSEN meeting in Paris.

28 Nov 2010

Segasist Technologies receives HTX funding for clinical validation of prostate MRI software

Segasist Technologies, a Canadian software company developing contouring productivity tools for medical imaging, has today announced the receipt of funding from The Health Technology Exchange (HTX) towards support of clinical validation of its software, to be conducted at the Lawson Health Research Institute and London Health Sciences Centre (London, Ontario). Experts from Sunnybrook Research Institute and Sunnybrook Health Sciences Centre will also participate in the validation process by providing input in the form of gold standard contours.

26 Nov 2010

HIV treatment drugs also help prevent HIV infection in high-risk men: Study

In a significant advance for HIV prevention research, a clinical trial confirms that the same drugs used for treating HIV can also help prevent HIV infection in the first place.

24 Nov 2010

Daily oral antiretroviral reduces HIV infection risk in MSM by 44%, study finds

A study that included nearly 2,500 HIV-negative men and transgender women who have sex with men has shown that a daily dose of Truvada, a pill containing the AIDS drugs emtricitabine and tenofovir, "can reduce risk of contracting [HIV] by an average of 44% - and by more than 70% if the subjects" follow the regimen closely, Los Angeles Times reports (Maugh, 11/23).

24 Nov 2010

Men failing to protect eyes from injuries: Experts

A review looking at patients attending a Melbourne hospital’s emergency department with a serious eye injury shows that most of them could be prevented by proper eye protection. Men’s particular lack of eye protection while using power tools and lawn mowers, usually during routine house maintenance, were the other major factors in the injury cases say the researchers.

23 Nov 2010

Study finds no link between prostate cancer clinical stage and risk of recurrence after radical prostatectomy

A new study challenges the current staging system that determines the extent or severity of prostate cancer that has not metastasized. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study found that there is no link between localized prostate cancer's clinical stage and a patient's risk of cancer recurrence after having his prostate removed.

22 Nov 2010

DoD recommends funding for Synta's STA-9584 for prostate cancer study

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the Department of Defense (DoD) has recommended STA-9584, a novel vascular disrupting agent (VDA) currently in pre-clinical development at Synta, be funded for study in advanced prostate cancer.

19 Nov 2010

Expert panel to endorse newly approved therapeutic vaccine for advanced prostate cancer

Provenge is one step closer to being covered by Medicare. An expert panel voted Wednesday to endorse the newly approved therapeutic vaccine for men with advanced prostate cancer.

19 Nov 2010

Men's Health News

MU nanomedicine experts form new partnership with Shasun Pharmaceuticals

Olympus PlasmaButton- vaporization technology now usable with Gyrus ACMI SuperPulse- Generator platform

FDA panel rejects expansion of drug label

FDA advisory committee votes against Avodart sNDA for prostate cancer risk reduction

American-style diet plays a vital role in prostate cancer, researchers say

Finger length may predict prostate cancer

Active surveillance improves quality of life in low-risk prostate cancer patients

Men with long index fingers at lower risk of prostate cancer

Researchers conduct real-time metabolic imaging in human patient with prostate tumor

Medivation, Astellas enroll 1,199 patients in MDV3100 Phase 3 AFFIRM study in advanced prostate cancer

FDA approves Axiron topical solution CIII for testosterone replacement therapy in men

Study finds association between DGKK gene and hypospadias

ESF report: Reduced male fertility may contribute to low birth rates

Segasist Technologies receives HTX funding for clinical validation of prostate MRI software

HIV treatment drugs also help prevent HIV infection in high-risk men: Study

Daily oral antiretroviral reduces HIV infection risk in MSM by 44%, study finds

Men failing to protect eyes from injuries: Experts

Study finds no link between prostate cancer clinical stage and risk of recurrence after radical prostatectomy

DoD recommends funding for Synta's STA-9584 for prostate cancer study

Expert panel to endorse newly approved therapeutic vaccine for advanced prostate cancer

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Latest News